GHK-Cu Explained: Copper Peptides in Skin Research

Deck: A copper-binding tripeptide found in human blood in 1973 has moved from wound-healing trials to cosmetic creams and, lately, injectable clinics. The laboratory story is real. The human evidence is smaller, older and more fragile than marketing suggests.

Three takeaways

• The peptide and its biology are real: GHK-Cu (copper tripeptide-1) is a naturally occurring human tripeptide with decades of consistent laboratory work behind it.
• Human evidence is thin and lopsided: the strongest controlled result is a 1994 diabetic wound trial; cosmetic trials are small, dated, partly unpublished or in non-indexed venues.
• Route matters: injected GHK-Cu has no completed controlled human trials, and FDA flags compounded injectable GHK-Cu for immunogenicity risk with limited human data. Skincare evidence cannot transfer to injections.

Evidence and status panel

Table of contents

1. [What GHK-Cu is — and what it isn’t](#s1) · 2. [Why skin researchers became interested](#s2) · 3. [What the laboratory evidence shows](#s3) · 4. [What the topical human trials found](#s4) · 5. [Study limitations](#s5) · 6. [Skin claims versus hair claims](#s6) · 7. [Why no two copper-peptide products behave the same](#s7) · 8. [Reading copper-peptide claims responsibly](#s8)

1. What GHK-Cu is — and what it isn’t

GHK is glycine–histidine–lysine, a three-amino-acid peptide isolated from human plasma in 1973 as the factor that kept normal liver cells alive in culture [1]; the sequence was identified in 1977 [2]. It occurs naturally in plasma, saliva and urine, and can be cut free from the alpha-2(I) chain of type I collagen — and from SPARC — when proteases break down injured tissue [3, 18]. Being a damage-released signal is part of this peptide’s real biology.

Its N-terminal motif grips copper(II) with very high affinity, forming the blue–green complex sold in cosmetic ingredient lists as Copper Tripeptide-1 [18, 24]. The grip is the rationale: copper is an essential cofactor for the lysyl-oxidase enzymes that cross-link newly made collagen [20]; GHK is, in effect, a tiny copper courier.

What it is not: an established medicine for skin, hair or “regeneration” — and not one standardised ingredient. “Copper peptide” labels can mean the copper complex, the copper-free tripeptide (Tripeptide-1), the lipid-attached derivative (Pal-GHK) or copper-acetate salts — and, as section 7 shows, what reaches skin differs by orders of magnitude.

2. Why skin researchers became interested

The founding idea is the repair-signal hypothesis: injury proteases release GHK from collagen, proposing it as an early local cue to rebuild extracellular matrix [3, 18]. Reviews report plasma GHK highest in young people — about 200 ng/mL at age 20, roughly 80 ng/mL by 60 [18] — and a 2023 comparison measured lower plasma GHK in COPD patients than age-matched controls (70.3 ± 38.9 vs 133.0 ± 54.5 ng/mL, P=0.009) [22]. Those are associations; nothing shows topping the level up would help.

Cells gave it substance. GHK-Cu stimulated collagen synthesis in cultured human fibroblasts from between 10-12 and 10-11 M, peaking near 10-9 M, without changing cell number [3]; at a similar nanomolar level, Stanford researchers saw faster fibroblast doubling and more basic FGF and VEGF — including fibroblasts from irradiated patients [7].

A mechanism is not a clinical benefit. All of it happened in dishes, reconstituted tissue or blood samples; getting a meaningful amount into living skin is the delivery problem the field took decades to face (section 7).

3. What the laboratory evidence shows

The literature is rich at the bottom of the evidence ladder and thin at the top [19, 20]; the ladder is explained in How to read a peptide study.

• Matrix: nanomolar GHK-Cu raises collagen synthesis in fibroblast cultures [3]; reviews add glycosaminoglycans and elastin [18].
• Growth factors: more basic FGF and VEGF from human fibroblasts at 10-9 M [7].
• Epidermis: in skin equivalents, copper-GHK raised basal-keratinocyte proliferation with more PCNA, p63 and integrins alpha-6/beta-1 — a “stemness” signature [8]; copper-free GHK did the same [9].
• Remodelling: in rat wound chambers, 2 mg GHK-Cu injections shifted the timing of MMP-2/-9 expression and activation during healing [4].
• Irritation: GHK-Cu was not cytotoxic in keratinocyte models and did not raise irritation biomarkers (IL-1alpha, IL-8, HSPA1A, FOSL1) where inorganic copper salts did [14]; reviews describe NF-kappa-B suppression too [18].

Two honesty notes: genome-wide claims (31.2% of measured human genes shifted >=50% [18]) come from Connectivity Map analyses led by the peptide’s discoverer — commercial interest declared, and ~35% of the entire literature includes him or his longtime collaborator [20]. And none of it tests what shoppers buy: a serum meeting living skin.

4. What the topical human trials found

Controlled human data are small, old and uneven; a 2026 aesthetic-medicine review counted 18 preclinical studies and two randomised trials [19].

Study card — strongest positive: diabetic foot ulcers (Mulder GD et al., Wound Repair Regen 1994 [5]). Multicentre, randomised, evaluator-blinded, vehicle-controlled trial; patient count not reported in the abstract. Diabetic neuropathic plantar ulcers on aggressive standard care (sharp debridement, offloading footwear, education). Daily metered GHK-Cu hydrogel (“Iamin”) versus identical vehicle; duration not reported. Median closure 98.5% vs 60.8% (P<0.05), about 3x faster; ulcers over 100 mm2: 89.2% vs -10.3% (P<0.01); infections 7% vs 34% (P<0.05). Adverse events, funding and gel concentration: not reported in the abstract. A drug-style wound test — not cosmetic skincare.

Study card — negative objective trial: post-laser skin (Miller TR et al., Arch Facial Plast Surg 2006 [6]). Circumoral CO2 laser resurfacing; randomised post-procedure regimen with or without GHK-Cu; blinded evaluators plus computerised image analysis; 13 completed; 12 weeks. No between-group difference in erythema resolution, wrinkles or objective quality — both groups improved; self-ratings favoured GHK-Cu (P=.04). Small sample; concentrations and funding not reported in the abstract.

Around those: the often-quoted 71-women facial-cream and 41-women eye-cream results exist only as 2002 American Academy of Dermatology meeting abstracts by industry-affiliated investigators — never full peer-reviewed papers [18]. A 1998 pilot compared thigh-skin ultrastructure after creams with vitamin C, a GHK-related copper-binding peptide, melatonin and tretinoin; the 2018 review reports consistent-with-increased-collagen changes in ~70% versus 50% and 40% [18] — a tiny pilot in a defunct journal. And a New Zealand randomised GHK-Cu serum study, reported with about 40 participants, was credited by the 2026 review with significant reductions in wrinkle volume and depth [19] — but its journal is not PubMed-indexed, so the numbers are reported, not independently verified.

The complete picture: one strong wound trial; one objective-negative cosmetic trial; one positive cosmetic trial in a low-visibility venue; industry abstracts.

5. Study limitations

• Every controlled trial dates from 1994–2016; a few dozen participants at most.
• The headline positive is a drug-style wound trial in diabetics — a weak base for cosmetic “rejuvenation” claims.
• Several abstracts omit concentrations and formulations, making trial-to-label comparison impossible; blinding a visibly blue compound was never described.
• About 35% of the 2005–2026 literature carries the discoverer’s-group authorship [18, 20]; 2026 reviews call the human record “thin and fragmented”, with too few well-designed trials [19, 20].

6. Skin claims versus hair claims

Skin claims rest on small fragile trials (section 5). Hair claims are weaker structurally. The best human hair trial did not test GHK-Cu: it tested a topical 5-aminolevulinic-acid + GHK complex — the GHK copper-free — in 45 men with pattern hair loss. After six months of daily use, hair counts rose 52.6 (100 mg/mL group) and 71.5 (50 mg/mL group) versus 9.6 on placebo, with significance reported only for the 50 mg/mL group; hair length and thickness did not change; no adverse events [11]. A two-component mixture cannot credit GHK, let alone GHK-Cu. The often-cited follicle biology mostly concerns AHK-Cu — alanyl-histidyl-lysine-Cu, a different peptide — active on ex vivo human follicles at 10-12 to 10-9 M [10]. Pattern-hair-loss treatment is a drug-level claim cosmetics cannot make [25]; for hair loss, see a dermatologist.

7. Why no two copper-peptide products behave the same

1. Molecule: Cu2+ complex (Copper Tripeptide-1) versus copper-free GHK, the palmitoylated derivative Pal-GHK, or copper-acetate salts — different chemistry, different safety scope [23, 24].
2. Hydrophilicity: log D -2.38 to -2.49 at pH 4.5–7.4 — GHK-Cu prefers water and barely partitions into the lipid-rich skin surface [16].
3. Penetration: intact skin models pass almost nothing in 9 hours; microneedles moved 134 ± 12 nmol of peptide and 705 ± 84 nmol of copper [13]. Ex vivo, a 0.68% aqueous solution under infinite-dose lab conditions delivered 136.2 ± 17.5 µg Cu/cm2 over 48 hours, 82 ± 8.1 retained [12] — mechanism-relevant, not a two-drop serum.
4. Stability: fine in water and pH 4.5–7.4 buffers (two weeks at 60 C), yet cleaved by base, oxidation and carboxypeptidases; excipient-sensitive (niosome-stable, less stable with dicetyl phosphate) [16].
5. Carriers: niosomes, liposomes, microneedles and ionic-liquid microemulsions (about three-fold delivery gain in mice [15]) reshape exposure [13, 17].
6. Purity and amount: commonly ~95% pure material [23]; typical cosmetic concentrations below 10 ppm, max surveyed 0.002% (one ~1% entry unconfirmed). The same name can span ~100-fold exposures.

A 2025 review: GHK-Cu and Pal-GHK are “widely used”, yet “there is a surprising absence of clinical studies using them” [17]. Label presence is not dermal exposure; exposure is not a proven outcome.

8. Reading copper-peptide claims responsibly

Three zones, three strengths. Biology: credible. Cosmetic appearance: plausible but modest — small, dated, partly unpublished trials, mostly versus vehicle, with self-report positives beside objective nulls. Treatment: not established. The wound-healing evidence is one 1994 drug-style trial in diabetics [5]; injected GHK-Cu has no completed controlled human trials [19, 21]; FDA flags compounded injectable GHK-Cu for immunogenicity risk with limited human data [26]. Skincare evidence cannot make an injection safe or effective, and blanket “regeneration” language is unwarranted for a cosmetic serum.

Two rules: cosmetic-trial results are not medical treatment, and wound-trial results are not anti-ageing proof. Judge the trials yourself with How to read a peptide study; continue with Copper-peptide skincare claims and Topical vs injectable GHK-Cu.

Explore the rest of this topic in the skin & copper-peptide topic hub.

Known limitations

• Sources checked 13 October 2026; the injectable marketplace and regulation move fast — recheck before republication and set the next review date.
• Several trial details (enrolment, funding, durations, concentrations) are unreported in available abstracts and labelled “not reported”, not estimated.
• The 2002 AAD abstracts, the 1998 pilot and the 2016 non-indexed wrinkle trial could not be independently verified: reported, not verified.
• No SAHPRA-based assessment for South African readers; no local legal claims made. No medical reviewer signed off yet; clinical/safety content requires review before publication. Education, not personal medical advice.

FAQ

Does GHK-Cu regenerate skin? Not as “regeneration” implies. Repair-related effects are consistent in cells and animal models [3, 4, 7, 8]; human trials are small and dated with mixed outcomes [5, 6, 19].

Is Copper Tripeptide-1 safe in cosmetics? The US CIR concluded it is safe as used at present concentrations — typically below 10 ppm in surveyed products [23]; an ingredient-level conclusion, not personal advice.

Is GHK the same as GHK-Cu? No. GHK is the tripeptide; GHK-Cu is its copper complex. Some products use the copper-free form (Tripeptide-1), which behaved similarly in skin-equivalent models [9].

What does the FDA safety flag mean? Route-specific: FDA lists GHK-Cu among bulk substances with potentially significant safety risks for injectable compounding — immunogenicity risk, limited human data [26]. A US statement, not a global ban.

Can copper peptides grow hair? Not proven: preclinical biology partly on a different peptide (AHK-Cu) [10], and one mixture trial (5-ALA + copper-free GHK) [11]. “Regrows hair” is a drug-level claim; see a dermatologist.

Sources

All numbered sources verified 13 October 2026 via PubMed/DOI or the official page named.

1. Pickart L, Thaler MM. Nat New Biol. 1973;243:85-7. PMID 4349963
2. Schlesinger DH, Pickart L, Thaler MM. Experientia. 1977;33:324-5. PMID 858356
3. Maquart FX, Pickart L, et al. FEBS Lett. 1988;238(2):343-6. PMID 3169264
4. Simeon A, et al. J Invest Dermatol. 1999;112(6):957-64. PMID 10383745
5. Mulder GD, et al. Wound Repair Regen. 1994;2(4):259-69. PMID 17147644
6. Miller TR, et al. Arch Facial Plast Surg. 2006;8(4):252-9. PMID 16847171
7. Pollard JD, et al. Arch Facial Plast Surg. 2005;7(1):27-31. PMID 15655171
8. Kang YA, et al. Arch Dermatol Res. 2009;301(4):301-6. PMID 19319546
9. Choi HR, et al. J Pept Sci. 2012;18(11):685-90. PMID 23019153
10. Pyo HK, et al. Arch Pharm Res. 2007;30(7):834-9. PMID 17703734 (AHK-Cu — different tripeptide)
11. Lee WJ, et al. Ann Dermatol. 2016;28(4):438-43. PMID 27489425 (5-ALA + GHK combination)
12. Hostynek JJ, Dreher F, Maibach HI. Inflamm Res. 2010;59(11):983-8. PMID 20703511 (PMC2945467)
13. Li H, et al. Pharm Res. 2015;32(8):2678-89. PMID 25690343
14. Li H, et al. Sci Rep. 2016;6:37664. PMID 27892491 (PMC5124859)
15. Liu T, et al. Bioact Mater. 2024;32:502-13. PMID 38026438 (PMC10643103)
16. Badenhorst T, Svirskis D, Wu Z. Pharm Dev Technol. 2016;21(2):152-60. PMID 25384620
17. Mortazavi SM, et al. Bioimpacts. 2025;15:30071. PMID 39963574 (PMC11830136)
18. Pickart L, Margolina A. Int J Mol Sci. 2018;19(7):1978. PMC6073405 — review by the peptide’s discoverer, with declared commercial interests; source of the 2002 AAD-abstract and 1998-pilot accounts
19. Mokhtar J, et al. Aesthet Surg J. 2026 (in press). PMID 42619529 — systematic review: 18 preclinical, 2 RCTs
20. Najafi N, et al. Arch Intern Med Res. 2026;9(3):269-93. PMC13604022 — notes ~35% of primary literature includes Pickart/Margolina (Skin Biology Inc.)
21. Mayfield CK, et al. Am J Sports Med. 2026;54(1):223-9. PMID 41476424
22. Deng M, et al. J Cachexia Sarcopenia Muscle. 2023;14(3):1365-80. PMID 36905132 (plasma GHK: COPD vs age-matched controls)
23. Cosmetic Ingredient Review. Tripeptide-1, Hexapeptide-12, their metal salts and fatty acyl derivatives, and Palmitoyl Tetrapeptide-7 (final 2014; published 2018). cir-safety.org/sites/default/files/tripep062014final.pdf
24. European Commission. CosIng: COPPER TRIPEPTIDE-1. ec.europa.eu/growth/tools-databases/cosing/details/55687
25. US FDA. Is It a Cosmetic, a Drug, or Both? fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
26. US FDA. Certain Bulk Drug Substances for Compounding That May Present Significant Safety Risks — GHK-Cu, “for injectable routes of administration”. fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

Non-indexed items, reported not verified: Leyden J, et al., AAD 60th Annual Meeting abstracts, New Orleans 2002, pp. 68-9; Abdulghani A, et al., Dis Manag Clin Outcomes. 1998;1:136-141 (both cited in [18]); Badenhorst T, et al., J Aging Sci. 2016;4:166 (outcome assertion in [19]).

Report a correction: https://getreta.co.za/corrections/ — corrections are reviewed and, when substantive, logged with dates; pages are never silently overwritten.

Related articles

• Copper-Peptide Skincare Claims: What Is Supported and What Is Marketing? — the next step on the same question: which shelf claims map to study endpoints, and which don’t.
• Topical vs Injectable GHK-Cu: Why the Route Changes the Question — what the FDA injectable flag means, and why topical trials cannot answer it.
• How to Read a Peptide Study Without Falling for the Hype — evaluate the trials cited above on your own terms.

Newsletter: The Peptide Science Brief — fortnightly research updates and evidence checks; explicit opt-in, one-click unsubscribe. https://getreta.co.za/newsletter/

Suggest a correction